SARS CoV 2 News and Research

RSS

Single-dose of COVID-19 mRNA vaccine reduces symptom duration

A study of workers administered the first dose of the BNT162b2 vaccine showed that they had reduced symptoms and faster viral clearance within six days of administration.

22 Jun 2021

Clinicians report cases of rare neurological disorder following COVID-19 vaccination

In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19.

22 Jun 2021

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

All coronaviruses produce four primary structural proteins and multiple nonstructural proteins. However, the majority of antibody-based SARS-CoV-2 research has focused on the spike and nucleocapsid proteins.

22 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Study identifies significant inequalities in the Liverpool 'mass testing' pilot

A study by the University of Liverpool has shown that while asymptomatic COVID-19 testing in Liverpool was popular, significant inequalities were evident between those who got tested and those who didn't.

21 Jun 2021

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

21 Jun 2021

Upper airway model derived from iPSCs paves the way for broader studies of viral lung infections

A team led by researchers at Newcastle University, UK has successfully created a model of the cells found in the lungs that can be used to replicate how COVID-19 infects the airways.

21 Jun 2021

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

A recent study by researchers from Poland, published in the journal Vaccines, shows how levels of IgA and IgG antibodies specific to the spike glycoprotein of SARS-CoV-2 increase in both breast milk and serum samples of mothers following vaccination against COVID-19 – with important implications for further vaccine planning endeavors.

21 Jun 2021

Could the European hedgehog be a sentinel for infectious agents and a harbinger of environmental pollution?

A recent review paper by Portuguese and Spanish authors, recently published in the journal Biologics, revealed the current state of knowledge regarding hedgehog health – most notably the presence of infectious agents, diseases and other threats that can affect the health of the population.

21 Jun 2021

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A new study in the journal Nature Communications describes the process of converting a SARS-CoV-2 antibody into a multivalent form, thus enabling it to bind at various different points with its epitope.

21 Jun 2021

Study reviews natural drug candidates for potential treatment of COVID-19

A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.

21 Jun 2021

Viral phosphoesterases (including in CoVs) can restrict antiviral innate immunity

An interesting new study describes the activities of a family of viral enzymes called two-histidine-phosphoesterases (2H-PEs), found in coronaviruses (CoVs) and rotaviruses, as well as a mammalian A-kinase anchoring protein enzyme, AKAP7, that shares the same function. Together called 2’,5’-PEs, these enzymes all break down 2’,5’-oligoadenylate compounds that activate the antiviral enzyme ribonuclease L (RNase L).

21 Jun 2021

Western diet increases COVID-19 severity in a hamster model

Researchers have shown that a Western diet may affect viral replication, disease severity, and immune protection following infection with SARS-CoV-2.

21 Jun 2021

Researchers identify four substances that inhibit SARS-CoV-2 replication in cells

Researchers from the German Center for Infection Research at Charité - Universitätsmedizin Berlin and the University of Bonn have examined the way in which SARS-CoV-2 reprograms the metabolism of the host cell in order to gain an overall advantage.

21 Jun 2021

COVID-19 studies should provide sex-disaggregated data, researchers warn

Researchers have warned that studies examining sex-specific responses to infection with SARS-CoV-2 must provide sex-disaggregated data.

21 Jun 2021

Research identifies SARS-CoV-2 cavities as potential drug targets

New research found the SARS-CoV-2 spike glycoprotein has druggable cavities with the best target being compatible with more than 1 billion compounds.

21 Jun 2021

Can a prior rhinovirus infection protect against COVID-19?

Researchers at the Yale School of Medicine found that rhinovirus accelerates interferon-stimulated genes.

21 Jun 2021

Study shows activation of CD16+ T-cells contribute to severe COVID-19 illness

Do T-cells play a protective immune role, or are they responsible for severe COVID-19 illness?

21 Jun 2021

Strategies against the development of SARS-CoV-2 vaccine escape mutants

In a recent paper the impact of a number of vaccination strategies is assessed with regards to the probability of inducing a SARS-CoV-2 vaccine escape mutants.

21 Jun 2021

Zinc inhibits SARS-CoV-2’s main protease in vitro

Zinc has antiviral properties. However, the detailed kinetics and the mechanism of zinc in the inhibition of viruses, particularly SARS-CoV-2 – the causative virus of COVID-19 – is unclear. To probe the role of zinc as an anti-SARS-CoV-2 agent at the structural and molecular level, researchers in India studied the binding kinetics and the inhibition mechanism of zinc with SARS-CoV-2’s viral proteins.

21 Jun 2021

SARS CoV 2 News and Research

Single-dose of COVID-19 mRNA vaccine reduces symptom duration

Clinicians report cases of rare neurological disorder following COVID-19 vaccination

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Study identifies significant inequalities in the Liverpool 'mass testing' pilot

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

Upper airway model derived from iPSCs paves the way for broader studies of viral lung infections

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

Could the European hedgehog be a sentinel for infectious agents and a harbinger of environmental pollution?

Multivalent antibodies show high potency against SARS-CoV-2 in new study

Study reviews natural drug candidates for potential treatment of COVID-19

Viral phosphoesterases (including in CoVs) can restrict antiviral innate immunity

Western diet increases COVID-19 severity in a hamster model

Researchers identify four substances that inhibit SARS-CoV-2 replication in cells

COVID-19 studies should provide sex-disaggregated data, researchers warn

Research identifies SARS-CoV-2 cavities as potential drug targets

Can a prior rhinovirus infection protect against COVID-19?

Study shows activation of CD16+ T-cells contribute to severe COVID-19 illness

Strategies against the development of SARS-CoV-2 vaccine escape mutants

Zinc inhibits SARS-CoV-2’s main protease in vitro

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News